German Govt Agrees Outlines Of Third-Stage Health Reform

6 October 1996

Germany's government coalition partners, under the chairmanship of Chancellor Helmut Kohl, have approved the main features of the third stage of the country's health service reform, set out in a position paper. Health Minister Horst Seehofer said the aim was to ensure the stability of health insurance contributions and that the reforms would be no "nature protection zone for uneconomic activities."

Full details of the further reforms are not yet all available but it is clear that the 72 million insured patients in Germany will have more rights, including the right to full information from doctors about their treatment and its cost.

Patients Will Have A Choice On Treatment Health fund patients will in future be able to choose between the current treatment process based on a card-deductible system, or treatment with an invoice for reimbursement. Insured people will be able to switch health funds if their existing fund increases the premium rate.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight